Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1398.4%.

  • Avidity Biosciences' EBITDA Margin rose 17198700.0% to 1398.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 2660.15%, marking a year-over-year increase of 235400.0%. This contributed to the annual value of 2932.23% for FY2024, which is 7418800.0% down from last year.
  • Per Avidity Biosciences' latest filing, its EBITDA Margin stood at 1398.4% for Q3 2025, which was up 17198700.0% from 4114.97% recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' EBITDA Margin peaked at 881.73% during Q1 2021, and registered a low of 7368.66% during Q1 2025.
  • For the 5-year period, Avidity Biosciences' EBITDA Margin averaged around 2470.0%, with its median value being 2079.53% (2023).
  • Data for Avidity Biosciences' EBITDA Margin shows a peak YoY increase of 17198700bps (in 2025) and a maximum YoY decrease of -54086200bps (in 2025) over the last 5 years.
  • Avidity Biosciences' EBITDA Margin (Quarter) stood at 2090.93% in 2021, then grew by 14bps to 1795.09% in 2022, then plummeted by -48bps to 2664.84% in 2023, then plummeted by -34bps to 3580.79% in 2024, then surged by 61bps to 1398.4% in 2025.
  • Its last three reported values are 1398.4% in Q3 2025, 4114.97% for Q2 2025, and 7368.66% during Q1 2025.